Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
Clinical trial NCT04220203 · APPROVED_FOR_MARKETING
Trial details
- NCT number
- NCT04220203
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Status
- APPROVED_FOR_MARKETING
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.